Linked Life Data

21205933

Source:http://linkedlifedata.com/resource/pubmed/id/21205933

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2011-3-1
pubmed:abstractText
Myostatin, a member of the transforming growth factor (TGF)-? superfamily, plays a potent inhibitory role in regulating skeletal muscle mass. Inhibition of myostatin by gene disruption, transgenic (Tg) expression of myostatin propeptide, or injection of propeptide or myostatin antibodies causes a widespread increase in skeletal muscle mass. Several peptides, in addition to myostatin propeptide and myostatin antibodies, can bind directly to and neutralize the activity of myostatin. These include follistatin and follistatin-related gene. Overexpression of follistatin or follistatin-related gene in mice increased the muscle mass as in myostatin knockout mice. Follistatin binds to myostatin but also binds to and inhibits other members of the TGF-? superfamily, notably activins. Therefore, follistatin regulates both myostatin and activins in vivo. We previously reported the development and characterization of several follistatin-derived peptides, including FS I-I (Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K. FASEB J 22: 477-487, 2008). FS I-I retained myostatin-inhibitory activity without affecting the bioactivity of activins. Here, we found that inhibition of myostatin increases skeletal muscle mass and decreases fat accumulation in FS I-I Tg mice. FS I-I Tg mice also showed decreased fat accumulation even on a control diet. Interestingly, the adipocytes in FS I-I Tg mice were much smaller than those of wild-type mice. Furthermore, FS I-I Tg mice were resistant to high-fat diet-induced obesity and hepatic steatosis and had lower hepatic fatty acid levels and altered fatty acid composition compared with control mice. FS I-I Tg mice have improved glucose tolerance when placed on a high-fat diet. These data indicate that inhibiting myostatin with a follistatin-derived peptide provides a novel therapeutic option to decrease adipocyte size, prevent obesity and hepatic steatosis, and improve glucose tolerance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1522-1555
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
300
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
E543-53
pubmed:meshHeading
pubmed-meshheading:21205933-Adipose Tissue, pubmed-meshheading:21205933-Animals, pubmed-meshheading:21205933-Blotting, Western, pubmed-meshheading:21205933-Diet, pubmed-meshheading:21205933-Fatty Acids, pubmed-meshheading:21205933-Fatty Liver, pubmed-meshheading:21205933-Follistatin, pubmed-meshheading:21205933-Glucose Tolerance Test, pubmed-meshheading:21205933-Liver, pubmed-meshheading:21205933-Mice, pubmed-meshheading:21205933-Mice, Inbred C57BL, pubmed-meshheading:21205933-Mice, Inbred mdx, pubmed-meshheading:21205933-Mice, Obese, pubmed-meshheading:21205933-Mice, Transgenic, pubmed-meshheading:21205933-Microscopy, Electron, Scanning, pubmed-meshheading:21205933-Muscle, Skeletal, pubmed-meshheading:21205933-Obesity, pubmed-meshheading:21205933-Phosphorylation, pubmed-meshheading:21205933-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:21205933-Smad3 Protein, pubmed-meshheading:21205933-Triglycerides
pubmed:year
2011
pubmed:articleTitle
Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis.
pubmed:affiliation
Division for Therapies against Intractable Diseases, Institute for Comprehensive Medical Science (ICMS), Fujita Health University, Toyoake, Aichi, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't